View Older Stories View More Recent Stories

Jul 21, 2015 08:00AM Merck Marks 30-Year Milestone in Commitment to Innovation and Care in HIV/AIDS
Jul 15, 2015 08:00AM Award-Winning Actress S. Epatha Merkerson, Merck and the American Diabetes Association Challenge African Americans with Type 2 Diabetes to Get to Their A1C Goal
Jul 7, 2015 07:00AM Allergan Enters Into Licensing Agreement with Merck to Obtain Exclusive Worldwide Rights to CGRP Migraine Development Program
Jun 29, 2015 08:30AM Merck Announces Phase 3 Study of Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiv
Jun 26, 2015 08:00AM Merck to Hold Second-Quarter 2015 Sales and Earnings Conference Call on July 28
Jun 11, 2015 09:00AM Liaison Technologies and Merck Cut the Ribbon for a Collaborative Innovation Center on NC State's Centennial Campus
Jun 11, 2015 08:00AM Merck Launches New Program That Encourages Women to "Rule the Real Talk" and Prioritize Their Sexual Health
Jun 10, 2015 08:46AM Merck and Samsung Bioepis Announce Pivotal Phase 3 Studies for Investigational Biosimilars SB4, Enbrel (Etanercept), and SB2, Remicade (Infliximab), Met Primary Endpoints
Jun 8, 2015 04:30PM TECOS, Merck’s Cardiovascular Safety Trial of JANUVIA (sitagliptin), Met Primary Endpoint in Patients with Type 2 Diabetes
Jun 3, 2015 05:00PM Results from Investigational IMPROVE-IT Study of VYTORIN® (ezetimibe and simvastatin) Published in the New England Journal of Medicine
Jun 1, 2015 04:34PM FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Advanced Non-Small Cell Lung Cancer, and Grants Priority Review
Jun 1, 2015 08:30AM Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies
Jun 1, 2015 08:00AM Findings Presented at 2015 ASCO Annual Meeting Add to Breadth of KEYTRUDA® (pembrolizumab) Data; Anti-Tumor Activity Now Demonstrated in 13 Different Tumor Types
May 30, 2015 02:00PM TESARO and Merck to Collaborate on a Combination Study of Niraparib and KEYTRUDA(R) (Pembrolizumab)
May 29, 2015 02:06PM New Findings Show Durable Anti-Tumor Activity with KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Head and Neck Cancer, Regardless of PD-L1 Expression Status
May 29, 2015 02:05PM First Study Evaluating DNA Mismatch Repair as Genetic Guide for Immunotherapy Treatment with Merck’s KEYTRUDA® (pembrolizumab) Presented at 2015 ASCO Annual Meeting and Published in the New England
May 29, 2015 08:30AM Amgen And Merck Announce Expansion Of Collaboration To Support Studies Of Talimogene Laherparepvec In Combination With KEYTRUDA® (Pembrolizumab) In Patients With Head And Neck Cancer
May 28, 2015 04:30PM Merck Submits U.S. New Drug Application for Grazoprevir/Elbasvir, an Investigational Once-Daily, Single Tablet Combination Therapy, for Treatment of Chronic Hepatitis C Genotypes 1, 4, and 6 Infection
May 28, 2015 08:30AM Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA® (pembrolizumab)
May 26, 2015 01:31PM Merck Announces Third-Quarter 2015 Dividend
May 26, 2015 06:33AM SIMPONI® (golimumab) Gains Positive Opinion from Committee for Medicinal Products for Human Use (CHMP) for the Treatment of Non-Radiographic Axial Spondyloarthritis
May 22, 2015 07:12AM Merck Receives Positive CHMP Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma
May 18, 2015 08:00AM Merck to Present at the UBS Global Healthcare Conference
May 13, 2015 05:00PM 2015 ASCO Annual Meeting: New Data in 10 Different Cancers from Merck’s Rapidly Expanding Immuno-Oncology Research Program for KEYTRUDA® (pembrolizumab) to be Presented
May 7, 2015 08:30AM Plexxikon and Merck to Collaborate on Combination Study Evaluating Investigational Immuno-oncology Regimen
Apr 28, 2015 05:50PM Market Wrap: Consumers Less Confident in April; Twitter Clipped on Q1 User Metrics; Biotechs Continue Slump
Apr 28, 2015 07:00AM Merck Announces First-Quarter 2015 Financial Results
Apr 27, 2015 06:30PM Merck Announces Publication of Pivotal Data from Phase 3 Clinical Studies of ZERBAXA™ (Ceftolozane/Tazobactam) in The Lancet and Clinical Infectious Diseases
Apr 27, 2015 05:00PM Merck Announces the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) Met Primary Endpoint
Apr 27, 2015 03:05PM Trading Radar for 4/28: Ford (F), Aetna (AET), Twitter (TWTR), GoPro (GPRO), Panera Bread (PNRA) Report
Apr 24, 2015 01:00AM Merck’s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
Apr 23, 2015 03:30AM Merck Announces Results from Phase 2/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir in Patients with Advanced Chronic Kidney Disease
Apr 22, 2015 08:00AM Tim McGraw, Merck and the American Diabetes Association Challenge Americans with Type 2 Diabetes to Get to Their A1C Goal
Apr 21, 2015 08:30AM Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th Annual ECCMID Congress
Apr 20, 2015 08:00AM TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumors
Apr 20, 2015 08:00AM TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination With KEYTRUDA(R) (pembrolizumab) in Solid Tumors
Apr 19, 2015 12:45PM Early Findings with KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting
Apr 19, 2015 08:30AM Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with KEYTRUDA® (pembrolizumab) Presented at AACR Annual Meeting and Published in the New England Journal of Medicine
Apr 19, 2015 08:30AM KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy...
Apr 19, 2015 08:00AM Merck Announces Submission of Supplemental Biologics License Application (sBLA) to U.S. FDA for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer
Apr 14, 2015 01:30PM Phase III Trial of the Merck and NewLink Genetics Investigational Ebola Vaccine Initiated in Sierra Leone
Apr 8, 2015 07:30AM Advaxis and Merck Announce Initiation of Enrollment in the Phase 1/2 Study of ADXS-PSA in Combination With Anti-PD-1 Therapy, KEYTRUDA(R) (pembrolizumab), for the Treatment of Advanced Prostate Cancer
Apr 8, 2015 07:30AM Advaxis and Merck Announce Initiation of Enrollment in the Phase 1/2 Study of ADXS-PSA in Combination With Anti-PD-1 Therapy, KEYTRUDA(R) (pembrolizumab), for the Treatment of Advanced Prostate Cancer
Apr 8, 2015 07:00AM Grazoprevir/Elbasvir, Merck’s Investigational Chronic Hepatitis C Therapy, Granted FDA Breakthrough Therapy Designations; New Phase 2 and 3 Data in Multiple HCV Patient Types to be Presented at The
Apr 6, 2015 08:00AM Merck Receives 2015 ENERGY STAR Sustained Excellence Award from U.S. Environmental Protection Agency
Mar 31, 2015 08:00AM Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma
Mar 27, 2015 08:00AM Merck to Hold First-Quarter 2015 Sales and Earnings Conference Call on April 28
Mar 26, 2015 08:30AM Merck Announces Collaboration with the American Diabetes Association to Educate Adults with Diabetes About Increased Risk for Serious Diseases like Pneumococcal Pneumonia
Mar 24, 2015 05:00PM Merck Announces New $10 Billion Share Repurchase Program
Mar 24, 2015 08:30AM Merck’s Pivotal KEYNOTE-006 Study in First-Line Treatment for Advanced Melanoma Met Co-Primary Endpoints and Will be Stopped Early
View More Recent Stories View Older Stories